News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Wall Street Realizes Myriad Genetics, Inc. (MYGN) Monopoly on Breast Cancer Risk Tests is Done



6/14/2013 6:47:42 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

You can’t patent a gene that occurs in nature, but you can patent one that you create. That’s the gist of the U.S. Supreme Court’s ruling today in a closely watched case that may have sweeping consequences for the biotech industry.

Myriad Genetics (MYGN) was defending patents it held on two gene mutations linked to increased risk of breast and ovarian cancer. “It found an important and useful gene, but groundbreaking, innovative, or even brilliant discovery does not by itself satisfy” the standard for patent eligibility, the court found. Justice Clarence Thomas wrote the opinion, with eight justices agreeing and Justice Antonin Scalia concurring.

Help employers find you! Check out all the jobs and post your resume.

Read at Business Week
Read at Forbes
Read at Boston Globe
Read at Washington Post
Read at CBS News
Read at The Street.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES